(NASDAQ: XLO) Xilio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.41%.
Xilio Therapeutics's earnings in 2026 is -$35,036,000.On average, 2 Wall Street analysts forecast XLO's earnings for 2026 to be -$14,717,647, with the lowest XLO earnings forecast at -$14,280,489, and the highest XLO earnings forecast at -$15,300,524. On average, 2 Wall Street analysts forecast XLO's earnings for 2027 to be -$39,247,059, with the lowest XLO earnings forecast at -$38,081,304, and the highest XLO earnings forecast at -$40,801,398.
In 2028, XLO is forecast to generate -$32,705,882 in earnings, with the lowest earnings forecast at -$31,734,420 and the highest earnings forecast at -$34,001,165.